Cargando…

Multifunctional Nanoparticles-Mediated PTT/PDT Synergistic Immune Activation and Antitumor Activity Combined with Anti-PD-L1 Immunotherapy for Breast Cancer Treatment

INTRODUCTION: Photoimmunotherapy is a breakthrough treatment for malignant tumors. Its uniqueness is that it uses antibody mediated targeted delivery to achieve high tumor specificity and uses laser-activated biophysical mechanism to accurately induce the rapid death of cancer cells and avoid damagi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Cunqing, Xu, Banghao, Qiu, Guanhua, Wei, Meng, Zhang, Mengqi, Bao, Shengxian, Tang, Jiali, Li, Lequn, Liu, JunJie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677922/
https://www.ncbi.nlm.nih.gov/pubmed/36419717
http://dx.doi.org/10.2147/IJN.S373282
_version_ 1784833896210235392
author Kong, Cunqing
Xu, Banghao
Qiu, Guanhua
Wei, Meng
Zhang, Mengqi
Bao, Shengxian
Tang, Jiali
Li, Lequn
Liu, JunJie
author_facet Kong, Cunqing
Xu, Banghao
Qiu, Guanhua
Wei, Meng
Zhang, Mengqi
Bao, Shengxian
Tang, Jiali
Li, Lequn
Liu, JunJie
author_sort Kong, Cunqing
collection PubMed
description INTRODUCTION: Photoimmunotherapy is a breakthrough treatment for malignant tumors. Its uniqueness is that it uses antibody mediated targeted delivery to achieve high tumor specificity and uses laser-activated biophysical mechanism to accurately induce the rapid death of cancer cells and avoid damaging the surrounding normal tissues. METHODS: In this paper, an iron-based micelle was designed to encapsulate the photothermal agent indocyanine green (ICG) and a cyclic tripeptide of arginine-glycine-aspartic acid (cRGD) as targeted multifunctional ICG@SANPs-cRGD nanoparticles for combined photothermal/photodynamic/immune therapy of breast cancer. RESULTS: The experimental results show that ICG@SANPs-cRGD nanoparticles have good biocompatibility and photothermal conversion ability. Photothermal therapy (PTT) and photodynamic therapy (PDT) based on ICG@SANPs-cRGD can not only inhibit the proliferation, invasion and migration of tumor cells, but also directly kill tumor cells by inducing apoptosis or necrosis. Dual-mode fluorescence light (FL) and magnetic resonance imaging (MRI) imaging in mice confirmed the selective accumulation at tumor sites and imaging ability of ICG@SANPs-cRGD. PTT/PDT combined with Anti-PD-L1 immunotherapy based on ICG@SANPs-cRGD mediated the immunogenic cell death (ICD) of tumor cells by regulating the expression of immune-related indicators and activated the body’s immune response mechanism, which enhanced the immunotherapy effect of immune checkpoint block (ICB). PTT/PDT combined with Anti-PD-L1 therapy not only prevented the progression of the primary tumor but also inhibited the distant metastasis of the tumor. DISCUSSION: This study explores the biomedical application of PTT/PDT combined with Anti-PD-L1 based on ICG@SANPs-cRGD nanomaterials for breast cancer treatment and demonstrates the potential of ICG@SANPs-cRGD as a multifunctional therapeutic platform for future cancer therapy.
format Online
Article
Text
id pubmed-9677922
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-96779222022-11-22 Multifunctional Nanoparticles-Mediated PTT/PDT Synergistic Immune Activation and Antitumor Activity Combined with Anti-PD-L1 Immunotherapy for Breast Cancer Treatment Kong, Cunqing Xu, Banghao Qiu, Guanhua Wei, Meng Zhang, Mengqi Bao, Shengxian Tang, Jiali Li, Lequn Liu, JunJie Int J Nanomedicine Original Research INTRODUCTION: Photoimmunotherapy is a breakthrough treatment for malignant tumors. Its uniqueness is that it uses antibody mediated targeted delivery to achieve high tumor specificity and uses laser-activated biophysical mechanism to accurately induce the rapid death of cancer cells and avoid damaging the surrounding normal tissues. METHODS: In this paper, an iron-based micelle was designed to encapsulate the photothermal agent indocyanine green (ICG) and a cyclic tripeptide of arginine-glycine-aspartic acid (cRGD) as targeted multifunctional ICG@SANPs-cRGD nanoparticles for combined photothermal/photodynamic/immune therapy of breast cancer. RESULTS: The experimental results show that ICG@SANPs-cRGD nanoparticles have good biocompatibility and photothermal conversion ability. Photothermal therapy (PTT) and photodynamic therapy (PDT) based on ICG@SANPs-cRGD can not only inhibit the proliferation, invasion and migration of tumor cells, but also directly kill tumor cells by inducing apoptosis or necrosis. Dual-mode fluorescence light (FL) and magnetic resonance imaging (MRI) imaging in mice confirmed the selective accumulation at tumor sites and imaging ability of ICG@SANPs-cRGD. PTT/PDT combined with Anti-PD-L1 immunotherapy based on ICG@SANPs-cRGD mediated the immunogenic cell death (ICD) of tumor cells by regulating the expression of immune-related indicators and activated the body’s immune response mechanism, which enhanced the immunotherapy effect of immune checkpoint block (ICB). PTT/PDT combined with Anti-PD-L1 therapy not only prevented the progression of the primary tumor but also inhibited the distant metastasis of the tumor. DISCUSSION: This study explores the biomedical application of PTT/PDT combined with Anti-PD-L1 based on ICG@SANPs-cRGD nanomaterials for breast cancer treatment and demonstrates the potential of ICG@SANPs-cRGD as a multifunctional therapeutic platform for future cancer therapy. Dove 2022-11-17 /pmc/articles/PMC9677922/ /pubmed/36419717 http://dx.doi.org/10.2147/IJN.S373282 Text en © 2022 Kong et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Kong, Cunqing
Xu, Banghao
Qiu, Guanhua
Wei, Meng
Zhang, Mengqi
Bao, Shengxian
Tang, Jiali
Li, Lequn
Liu, JunJie
Multifunctional Nanoparticles-Mediated PTT/PDT Synergistic Immune Activation and Antitumor Activity Combined with Anti-PD-L1 Immunotherapy for Breast Cancer Treatment
title Multifunctional Nanoparticles-Mediated PTT/PDT Synergistic Immune Activation and Antitumor Activity Combined with Anti-PD-L1 Immunotherapy for Breast Cancer Treatment
title_full Multifunctional Nanoparticles-Mediated PTT/PDT Synergistic Immune Activation and Antitumor Activity Combined with Anti-PD-L1 Immunotherapy for Breast Cancer Treatment
title_fullStr Multifunctional Nanoparticles-Mediated PTT/PDT Synergistic Immune Activation and Antitumor Activity Combined with Anti-PD-L1 Immunotherapy for Breast Cancer Treatment
title_full_unstemmed Multifunctional Nanoparticles-Mediated PTT/PDT Synergistic Immune Activation and Antitumor Activity Combined with Anti-PD-L1 Immunotherapy for Breast Cancer Treatment
title_short Multifunctional Nanoparticles-Mediated PTT/PDT Synergistic Immune Activation and Antitumor Activity Combined with Anti-PD-L1 Immunotherapy for Breast Cancer Treatment
title_sort multifunctional nanoparticles-mediated ptt/pdt synergistic immune activation and antitumor activity combined with anti-pd-l1 immunotherapy for breast cancer treatment
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677922/
https://www.ncbi.nlm.nih.gov/pubmed/36419717
http://dx.doi.org/10.2147/IJN.S373282
work_keys_str_mv AT kongcunqing multifunctionalnanoparticlesmediatedpttpdtsynergisticimmuneactivationandantitumoractivitycombinedwithantipdl1immunotherapyforbreastcancertreatment
AT xubanghao multifunctionalnanoparticlesmediatedpttpdtsynergisticimmuneactivationandantitumoractivitycombinedwithantipdl1immunotherapyforbreastcancertreatment
AT qiuguanhua multifunctionalnanoparticlesmediatedpttpdtsynergisticimmuneactivationandantitumoractivitycombinedwithantipdl1immunotherapyforbreastcancertreatment
AT weimeng multifunctionalnanoparticlesmediatedpttpdtsynergisticimmuneactivationandantitumoractivitycombinedwithantipdl1immunotherapyforbreastcancertreatment
AT zhangmengqi multifunctionalnanoparticlesmediatedpttpdtsynergisticimmuneactivationandantitumoractivitycombinedwithantipdl1immunotherapyforbreastcancertreatment
AT baoshengxian multifunctionalnanoparticlesmediatedpttpdtsynergisticimmuneactivationandantitumoractivitycombinedwithantipdl1immunotherapyforbreastcancertreatment
AT tangjiali multifunctionalnanoparticlesmediatedpttpdtsynergisticimmuneactivationandantitumoractivitycombinedwithantipdl1immunotherapyforbreastcancertreatment
AT lilequn multifunctionalnanoparticlesmediatedpttpdtsynergisticimmuneactivationandantitumoractivitycombinedwithantipdl1immunotherapyforbreastcancertreatment
AT liujunjie multifunctionalnanoparticlesmediatedpttpdtsynergisticimmuneactivationandantitumoractivitycombinedwithantipdl1immunotherapyforbreastcancertreatment